The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered
- PMID: 36746172
- DOI: 10.1016/S0140-6736(23)00059-4
The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered
Conflict of interest statement
AE reports research funding from Pfizer, Eli Lilly and Company, Novartis, Bristol-Myers Squibb, AbbVie, Janssen, and Boehringer Ingelheim, and honoraria as consultant or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma, Galápagos, Sun Pharmaceuticals, Samsung Bioepis, Pfizer, Eli Lilly, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen. JPT reports consulting fees from Coloplast; speakers fees from Pfizer, AbbVie, Regeneron, Sanofi-Genzyme, LEO Pharma, Eli Lilly, and Almirall; and advisory board fees from Pfizer, AbbVie, Regeneron, Sanofi-Genzyme, LEO Pharma, Eli Lilly, Almirall, Arena Pharmaceuticals, Aslan Pharmaceuticals, OM Pharma, and RAPT Therapeutics.
Comment on
-
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical